May 21, 2019

Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy

MIT Professors Robert S. Langer and Shuguang Zhang as Co-Principal Investigators

Plan to Utilize Innovative “QTY Code" Modified Proteins as Novel Therapeutic Targets

FREEHOLD, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- **Avalon GloboCare Corp. (NASDAQ: AVCO)**, a leading global developer of cell-based technologies and therapeutics, today announced it has entered into a sponsored research and licensing agreement with Massachusetts Institute of Technology (MIT) to generate novel therapeutic targets for cellular therapy using artificial intelligence (AI) enhanced protein design “QTY Code” technology. This breakthrough technology of “QTY Code” greatly enhances the solubility of designer peptides and proteins, therefore expanding the repertoire of selected therapeutic targets against cancers and other diseases. Avalon will initiate research and development with MIT professors Robert S. Langer and Shuguang Zhang to design the next generation of therapeutics for Cytokine Release Syndrome, T-cell leukemia, as well as novel methodology to re-engineer immune cells for cellular immunotherapy.

“We are very excited to engage with MIT to develop and apply this cutting-edge AI-enhanced protein design QTY Code technology under the expert guidance of Professors Langer and Zhang,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. “This will tremendously enrich our upstream innovative development targets and it will be designed to integrate seamlessly with our state-of-the-art bio-production facility as well as our downstream clinical management of patients undergoing cellular therapy,” added Dr. Jin.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics ("liquid biopsy"), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking

statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com

Source: Avalon GloboCare Corp.